NCT00972504

723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover

A Randomised, Double-blind, Placebo-controlled 4-period Cross-over Study to Assess the Efficacy and Safety of Repeat Dose Intranasal GSK1004723 (1000µg), Oral GSK835726 (10mg) and Cetirizine (10mg) in the Environmental Challenge Chamber in Subjects With Seasonal Allergic Rhinitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a randomised, double-blind, placebo-controlled 4-period cross-over study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000µg), oral GSK835726 (10mg) and cetirizine (10mg) in the environmental challenge chamber in subjects with seasonal allergic rhinitis.

Conditions

• Rhinitis, Allergic, Seasonal

Interventions

Type	Name	Description
DRUG	GSK835726 10mg	GSK835726 10mg tablet
DRUG	GSK1004723 1000mcg	GSK1004723 1000mcg nasal spray solution
DRUG	Cetirizine 10mg	Cetirizine 10mg active comparator
DRUG	placebo	placebo to match actives

Timeline

• Start date: 2009-06-01
• Primary completion: 2009-08-01
• Completion: 2009-08-14
• First posted: 2009-09-07
• Last updated: 2017-08-02
• Results posted: 2017-08-02

Locations

1 site across 1 country: Germany